Literature DB >> 15457463

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.

Bernard Vandooren1, Elli Kruithof, David T Y Yu, Markus Rihl, Jieruo Gu, Leen De Rycke, Filip Van Den Bosch, Eric M Veys, Filip De Keyser, Dominique Baeten.   

Abstract

OBJECTIVE: To investigate the role of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in spondylarthropathy (SpA) synovitis.
METHODS: Paired samples of synovial biopsy tissue as well as serum and synovial fluid (SF) from 41 patients with SpA and 20 patients with rheumatoid arthritis (RA) and serum samples from 20 healthy controls were analyzed by immunohistochemistry and enzyme-linked immunosorbent assay for the presence of MMPs 1, 2, 3, and 9 and TIMPs 1 and 2. In addition, sera from 16 patients with ankylosing spondylitis (AS) and peripheral synovitis and 17 patients with AS and exclusively axial involvement were analyzed. An additional cohort of SpA patients was analyzed at baseline and after 12 weeks of infliximab treatment.
RESULTS: Staining for MMPs and TIMPs showed a cellular and interstitial pattern in the synovial lining and sublining layers that was similar between the RA and SpA patients. Involvement of MMPs and TIMPs in SpA synovitis was suggested by the correlation with cellular infiltration, vascularization, and cartilage degradation. Higher serum levels of MMPs 3 and 9 were revealed in SpA and RA patients as compared with healthy controls. Production of MMP-3, but not MMP-9, in the serum reflected the presence of peripheral synovitis, as indicated by 1) the correlation between serum levels, SF levels (which were 1,000-fold higher than the serum levels), and synovial expression of MMP-3, 2) the increased levels of MMP-3 in AS patients with peripheral disease and not exclusively axial involvement, and 3) the correlation of serum and SF MMP-3 with parameters of synovial, but not systemic, inflammation. The modulation of the MMP/TIMP system by tumor necrosis factor alpha (TNFalpha) blockade was confirmed by the down-regulation of all MMPs and TIMPs in the synovium and a pronounced and rapid decrease of serum MMP-3.
CONCLUSION: MMPs and TIMPs are highly expressed in SpA synovitis and mirror both the inflammatory and tissue-remodeling aspects of the local disease process. Serum MMP-3, originating from the inflamed joint, represents a valuable biomarker for peripheral synovitis. Modulation of the MMP/TIMP system by infliximab could contribute to the antiinflammatory and tissue-remodeling effects of TNFalpha blockade in SpA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15457463     DOI: 10.1002/art.20477

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  51 in total

1.  Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.

Authors:  E Kruithof; D Baeten; F Van den Bosch; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-09-23       Impact factor: 19.103

Review 2.  Biomarkers in spondyloarthritis.

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

3.  Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.

Authors:  Susanne Juhl Pedersen; Merete Lund Hetland; Inge Juul Sørensen; Mikkel Ostergaard; Hans Jørgen Nielsen; Julia Sidenius Johansen
Journal:  Clin Rheumatol       Date:  2010-07-18       Impact factor: 2.980

Review 4.  Novel therapies for ankylosing spondylitis.

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 5.  Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?

Authors:  M D Smith; D Baeten; A-K Ulfgren; I B McInnes; O Fitzgerald; B Bresnihan; P P Tak; D Veale
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

Review 6.  Pathogenesis of spondyloarthritis: insights from synovial membrane studies.

Authors:  Leen De Rycke; Elli Kruithof; Bernard Vandooren; Paul P Tak; Dominique Baeten
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

Review 7.  Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?

Authors:  M M Ward
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

8.  Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment.

Authors:  M Rihl; E Kruithof; C Barthel; F De Keyser; E M Veys; H Zeidler; D T Y Yu; J G Kuipers; D Baeten
Journal:  Ann Rheum Dis       Date:  2005-04-07       Impact factor: 19.103

9.  Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes.

Authors:  Yi-Kun Mou; Ping-Ping Zhang; Qiu-Xia Li; Zhi-Ming Lin; Ze-Tao Liao; Qiu-Jing Wei; Jie-Ruo Gu
Journal:  Clin Rheumatol       Date:  2015-04-26       Impact factor: 2.980

10.  Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis.

Authors:  Consuelo Romero-Sánchez; William H Robinson; Beren H Tomooka; John Londoño; Rafael Valle-Oñate; Feng Huang; Xiaohu Deng; Liyun Zhang; Chunhua Yang; David Tak Yan Yu
Journal:  Clin Rheumatol       Date:  2008-06-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.